BRCA1 and metastatic prostate carcinoma: While nearly all patients with breast, ovarian, pancreatic, and metastatic prostate cancer meet the NCCN criteria for BRCA1/2 germline testing, one study reported that only 75% of ovarian, 69% of breast, 40% of pancreas, and 18% of patients with prostate cancer had knowledge of their BRCA1/2 carrier status prior to undergoing tumor CGP25.